Essential Pharma

Company snapshot

Essential Pharma is an international specialty pharmaceutical company dedicated to maintaining access to clinically differentiated, niche medicines in small patient populations. Our high-impact portfolio has a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease, and our products treat patients in more than 70 countries. We are proactive in identifying low v

• 4 approved product(s) across US/EU regulatory metadata.
• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 95 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Essential Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Essential Pharma.

1. May 23, 2026 Clinical update

   SENTI-202 — Phase 1

2. May 23, 2026 Clinical update

   SN301A — Phase 1

3. Sep 23, 2025 Patent grant

   Methods for treating subjects with Prader-Willi syndrome

4. Jul 8, 2025 Patent grant

   Compositions and methods for treatment of skin-related diseases and promoting dermatological health

5. Jul 1, 2025 Patent grant

   Dosage regimen for pegylated interferon

View all clinical trial activity →

• What is Essential Pharma?

  Essential Pharma is a pharma organization headquartered in Egham, GB. It trades on NYSE under ticker SNTI. Primary therapeutic focus areas include AML/MDS, Hepatocellular Carcinoma (HCC). NovaPharmaNews links 2 clinical program(s), 3 drug profile(s), and 95 patent record(s) to th

• Is Essential Pharma publicly traded?

  Yes. Essential Pharma is listed with ticker SNTI on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Essential Pharma develop or market?

  We link 3 drug profile(s) where Essential Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/senti-biosciences-holdings#company-drugs.

• What are the latest developments for Essential Pharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 4 US patent grant(s) tied to this profile.

• What therapeutic areas does Essential Pharma focus on?

  Essential Pharma focuses on AML/MDS, Hepatocellular Carcinoma (HCC) based on our analysis of their pipeline programs and drug development activities.